Latest News

Actively Advocating: Widening the Access to MS Treatments

April 7, 2020 | Advocacy, Treatments

In February Pharmac published the minutes of the Pharmacology and Therapeutics Advisory Committee’s (PTAC) November 2019 meeting. The minutes reported the outcome of the meeting at which MSNZs submission to widen the Special Authority (SA) access criteria for disease modifying […]


Ocrelizumab approved for funding

October 7, 2019 | Advocacy, Life with MS, Treatments

Media Release – 7 October 2019 Hundreds with Multiple Sclerosis ‘Abandoned’ due to Pharmac Drug Access Criteria There’s concern that a Pharmac decision to fund the drug Ocrelizumab (Ocrevus) for certain patients with multiple sclerosis from December 1st will still […]


NEDTALKS – Important conversations about your brain

August 22, 2019 | Education, Event, Life with MS, Treatments

MS Taranaki NED TALKS on Brain Health: Time Matters Saturday 31st August, 10am to 3pm (lunch included) at Plymouth International (Quality Hotel), 220 Courtenay Street, New Plymouth. Hosted by Graham Walker, President MS Taranaki Inc with invited guests from the […]


Consultation for the funding of Ocrelizumab for RRMS

August 9, 2019 | Life with MS, Treatments

Pharmac announced on Wednesday 7th August, that they are now publicly consulting on the proposed funding of Ocrelizumab for Relapsing Remitting MS. MSNZ welcomes this announcement which we have been advocating for since May 2017. To read more about our […]


Safety Review into Alemtuzumab (Lemtrada)

April 16, 2019 | Treatments

The European Medicines Agency (EMA) announced on the 12th April it is conducting a review into the safety of MS drug alemtuzumab (Lemtrada). The EMA has launched the safety review ‘following new reports of immune-mediated conditions (caused by the body’s […]